Enteric fever, commonly known as typhoid fever, is a systemic infection caused by Salmonella Typhi or Paratyphi. Despite advancements in diagnostic methods and treatment, it remains a significant global health issue, particularly in low-resource settings. This article aims to provide a comprehensive guide for healthcare professionals to optimize diagnosis and treatment strategies for enteric fever.
Diagnosing enteric fever can be challenging due to its nonspecific symptoms and the limitations of current diagnostic tests. Blood culture, the gold standard for diagnosis, has a sensitivity of only 40-60%. There is a pressing need for improved diagnostic tools that are both accurate and practical for use in resource-limited settings.
Recent advancements have led to the development of rapid diagnostic tests (RDTs), which offer promising results. These tests, based on the detection of specific antigens or antibodies, provide results within hours. However, more research is needed to establish their reliability and cost-effectiveness.
The mainstay of treatment for enteric fever is antibiotic therapy. However, the emergence of multi-drug resistant (MDR) strains has complicated treatment strategies. Fluoroquinolones have been the drugs of choice, but resistance to these is increasing, necessitating the use of third-generation cephalosporins or azithromycin.
With the rising trend of antibiotic resistance, the future lies in vaccine development. Current vaccines have limitations, but new-generation vaccines are under development. In addition, novel therapeutic strategies, such as the use of bacteriophages, are being explored.
Optimizing the diagnosis and treatment of enteric fever requires a multifaceted approach, encompassing the development of improved diagnostic tools, effective treatment regimens, and preventive measures. By staying abreast of emerging strategies, healthcare professionals can play a crucial role in managing this global health issue.
1.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
2.
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
3.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
4.
In early dementia, SSRIs enhance cognition and major depression.
5.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
1.
Oncologic Emergencies: Diagnosis and Treatment
2.
Strategic Standards in Hematology for Specialists
3.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
4.
Advanced Breakthroughs in Hematology and Patient Outcomes
5.
Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part IX
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation